In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with a price target of $7.00. The company’s shares closed yesterday at ...
BOSTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback